Articles related to LYMPHOMA

The bispecific antibody targets both CD20 and CD3 proteins and has demonstrated the capacity of activated immune cells to eliminate lymphoma cells, achieving deep and potentially curable remissions.

With a complete metabolic response rate of 82.1% after just four cycles of induction, this new regimen could change how we approach treatment for young patients with low risk, relapsed classical Hodgkin lymphoma.

The recent approval of epcoritamab for R/R DLBCL introduces a new pathway in treatment, offering substantial response rates and the potential for broader implementation beyond academic centers. Explore the detailed insights into the function, efficacy, and prospective implications of this novel therapy.

Uncover the potential of nivolumab and axicabtagene ciloleucel as they showcase promising results in the latest lymphoma trials, potentially reshaping the standard of care for these malignancies.

Amid emerging safety concerns, ADC Therapeutics has paused its mid-stage trial of Zynlonta, a potential game-changer in treating certain types of blood cancer, calling into question the drug’s future trajectory.

Explore the newest developments in lymphoma therapy with the help of this CME program, learn how effective bispecific antibodies and antibody-drug conjugates are, and fine-tune your therapeutic approaches.